An ongoing dialogue on HIV/AIDS, infectious diseases,
March 1st, 2009
Sedation for Colonoscopies in HIV Patients: Debate Rages
Here’s a problem we’re grappling with:
A patient with HIV needs a colonoscopy, but is on either a ritonavir-boosted protease inhibitor or an efavirenz-based regimen.
(This must be something like 90% of HIV patients as of March 1, 2009, based on my extremely unscientific gut impression.)
For efavirenz, midazolam is contraindicated; for ritonavir, same story — or “consider therapy modification”, according to one source I found. Ditto fentanyl.
So what should be given for sedation? (Important side note: if you told me pre-1996 that this would be a critical management question for my HIV patients, I would have thought you were out of your mind.)
Lots of different views here in Boston, including:
- Give the usual meds, titrate to effect
- NEVER give midazolam with either efavirenz or ritonavir; instead, use lorazepam, etc
- Stop HIV meds 1 day in advance, then give midazolam and fentanyl
Does anyone know? Or does anyone have sufficient experience to share?
Categories: Antiretroviral Rounds, HIV, Patient Care
Tags: colonoscopy, fentanyl, HIV, hiv patients, lorazepam, midazolam, protease, protease inhibitor, titrate
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
4 Responses to “Sedation for Colonoscopies in HIV Patients: Debate Rages”

Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.
Search this Blog
Follow HIV and ID Observations Posts via Email
Archives
Most Popular Posts
- When AI Gets the Medical Advice Wrong — and Right
- ID Things to Be Grateful for — 2025 Edition
- What Use Is the Physical Examination in Current Medical Practice?
- Dengue, Malaria, HIV Cure, and Others — First Cold Snap of the Winter ID Link-o-Rama
- SNAP Trial Helps Resolve Long-Running Controversies Over Management of Staph Bacteremia
-
From the Blog — Most Recent Articles
- What Use Is the Physical Examination in Current Medical Practice? December 17, 2025
- Dengue, Malaria, HIV Cure, and Others — First Cold Snap of the Winter ID Link-o-Rama December 10, 2025
- ID Things to Be Grateful for — 2025 Edition November 24, 2025
- When AI Gets the Medical Advice Wrong — and Right November 18, 2025
- Hot Takes from IDWeek: CDC, COVID, and Two Doses of Dalbavancin November 13, 2025
FROM NEJM — Recent Infectious Disease Articles- Interactive Perspective: Measles December 18, 2025This Double Take video reviews evidence-based recommendations on measles prevention and management and explores commonly asked questions about the measles virus and infection.
- Noninferiority of One HPV Vaccine Dose to Two Doses December 18, 2025In this trial, one dose of an HPV vaccine was noninferior to two doses in preventing HPV type 16 or 18 infection.
- From Crisis to Action — Policy Pathways to Reverse the Rise in Congenital Syphilis December 18, 2025In recent years, cases of congenital syphilis have surged. This trend reflects both prenatal care gaps and systemic issues, including failures in testing, treatment, and public health infrastructure.
- Contact Precautions for MRSA and Vancomycin-Resistant Enterococcus December 18, 2025This feature about the use of contact precautions in the hospital for patients with MRSA or VRE offers a case vignette accompanied by two essays, one supporting continuing the use of contact precautions and the other recommending discontinuing them.
- Evidence to Action — Single-Dose HPV Vaccination and Cervical HPV Infection December 18, 2025Kreimer and colleagues now report in the Journal1 the results of the ESCUDDO trial, which showed that the efficacy of a single dose of either a bivalent human papillomavirus (HPV) vaccine or a nonavalent formulation was similar to that of the standard two-dose schedule. This randomized trial...
- Interactive Perspective: Measles December 18, 2025
-
Tag Cloud
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball Brush with Greatness CDC C diff COVID-19 CROI darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease medical education MRSA PEP PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster

I would titrate to effect. After all, we use fentanyl patches in patients on efavirenz. You just start at a lower dose.
Paul, I would sedate as usual as it has been my experience (hundreds of cases of endoscopy in patients on these meds) that there are no significant adverse effects, and there are no cases of clinically relevant drug interactions using fentanyl/midazolam for conscious sedation in patients on these agents (thousands of cases). Until it is a clinical relevant interaction (vs pharmacological or theoretical effect as it is at this time), deviating from a safe and time-tested sedation strategy for endoscopy does not seem justified.
Brian, many thanks for your input — will share with our colleagues.
Paul
[…] HIV-Infected Endoscopy Patients Posted by M. Brian Fennerty on March 14th, 2009 In a recent blog post, ID expert Paul Sax raised the question of which sedatives should be used when scoping HIV-infected […]